Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3133373
Max Phase: Preclinical
Molecular Formula: C62H87N17O15S4
Molecular Weight: 1438.75
Molecule Type: Protein
Associated Items:
ID: ALA3133373
Max Phase: Preclinical
Molecular Formula: C62H87N17O15S4
Molecular Weight: 1438.75
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](C)NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(N)=O)CSSC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2
Standard InChI: InChI=1S/C62H87N17O15S4/c1-9-29(4)48-61(93)70-32(7)52(84)72-43(20-36-22-65-27-67-36)55(87)68-30(5)53(85)75-45-25-97-98-26-46(59(91)78-48)76-56(88)41(18-34-14-16-37(81)17-15-34)71-51(83)31(6)69-60(92)47(28(2)3)77-54(86)39(63)23-95-96-24-44(50(64)82)74-62(94)49(33(8)80)79-57(89)42(73-58(45)90)19-35-21-66-40-13-11-10-12-38(35)40/h10-17,21-22,27-33,39,41-49,66,80-81H,9,18-20,23-26,63H2,1-8H3,(H2,64,82)(H,65,67)(H,68,87)(H,69,92)(H,70,93)(H,71,83)(H,72,84)(H,73,90)(H,74,94)(H,75,85)(H,76,88)(H,77,86)(H,78,91)(H,79,89)/t29-,30-,31-,32-,33+,39-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
Standard InChI Key: SFJJPEDFFDAUFM-UUPKQVJKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1438.75 | Molecular Weight (Monoisotopic): 1437.5450 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Meinander K, Weisell J, Pakkala M, Tadd AC, Hekim C, Kallionpaa R, Widell K, Stenman U, Koistinen H, Narvanen A, Vepsalainen J, Luthman K, Wallen EAA. (2013) Pseudopeptides with a centrally positioned alkene-based disulphide bridge mimetic stimulate kallikrein-related peptidase 3 activity, 4 (3): [10.1039/C3MD20292E] |
Source(1):